LEXARIA BIOSCIENCE CORP. Net Fee Amt
LEXARIA BIOSCIENCE CORP. (LEXX) had Net Fee Amt of $194 as of 2025-12-29, per its S-1 filed 2025-12-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2025-12-29
- 2025-12-29: Net Fee Amt $194.00.
| Period end | Net Fee Amt |
|---|---|
| 2025-12-29 | $194.00 S-1 · filed 2025-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |